drugset / Trial / NCT05219864

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

NCT05219864

Phase 3 Withdrawn Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

Timeline

Start
2023-01-31
Primary completion
2024-04-25
Completion
2024-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 1.5 % Topical

Indications